Ipamorelin + CJC-1295 Stack

Complete guide to stacking Ipamorelin with CJC-1295. Synergistic benefits, dosing protocols, and what to expect.

Ipamorelin: Clinical TrialsCJC-1295: Clinical Trials

Stack Overview

The Ipamorelin + CJC-1295 stack is the gold standard for GH peptide combinations. Ipamorelin provides clean GH pulses while CJC-1295 extends GH release duration, creating sustained elevation without significant side effects.

Ipamorelin

Clinical Trials

A selective growth hormone secretagogue that stimulates GH release without significantly affecting cortisol or prolactin. Considered one of the safest GHRPs.

Typical Dose

200-300 mcg 2-3x daily

View full profile

CJC-1295

Clinical Trials

A synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates GH release from the pituitary. Often combined with a GHRP like Ipamorelin for synergistic effects.

Typical Dose

100 mcg daily (no DAC) or 2 mg weekly (with DAC)

View full profile

Synergistic Benefits

Combining a GHRP (Ipamorelin) with a GHRH analog (CJC-1295) amplifies GH release beyond either alone. Ipamorelin provides selective GH pulses without affecting cortisol or prolactin, while CJC-1295 sustains elevated GH levels.

Enhanced natural GH release
Improved body composition (muscle gain, fat loss)
Better sleep quality
Faster recovery from training
Skin and hair improvements
Anti-aging benefits

Stack Dosing Protocol

Standard protocol: Ipamorelin 100-300 mcg + CJC-1295 (no DAC) 100-300 mcg, taken 2-3 times daily. Usually taken together in the same injection. Common timing: morning (fasted), post-workout, and before bed.

PeptideDoseFrequencyTiming
Ipamorelin200-300 mcg 2-3x daily2-3x dailyBefore bed or morning (fasted)
CJC-1295100 mcg daily (no DAC) or 2 mg weekly (with DAC)Daily (no DAC) or 1-2x weekly (with DAC)Before bed

Timing Considerations

Take Ipamorelin and CJC-1295 together - they work best when combined in the same injection. Best taken on empty stomach (fasted state). Wait 20-30 minutes before eating. Before bed dosing enhances natural nighttime GH pulse.

What to Expect

Week 1-2

GH release beginning. Sleep improvements often noticed first. May experience mild water retention. Some users feel increased energy.

Week 3-4

GH levels consistently elevated. Recovery from workouts notably better. Sleep quality improved. Subtle body composition changes beginning.

Week 5-8

Visible changes in body composition. Fat loss becoming apparent. Muscle recovery significantly enhanced. Skin quality improvements noticeable.

Important Considerations

  • Not FDA-approved peptides
  • May affect blood sugar - monitor if diabetic
  • Water retention possible during initial weeks
  • Avoid taking with high-fat meals (reduces absorption)
  • Start with lower doses to assess tolerance

Frequently Asked Questions

Can you stack Ipamorelin with CJC-1295?

Yes, Ipamorelin and CJC-1295 are designed to work together. Ipamorelin (a GHRP) and CJC-1295 (a GHRH analog) act through different pathways that synergize for enhanced growth hormone release.

What are the benefits of this stack?

Combining a GHRP (Ipamorelin) with a GHRH analog (CJC-1295) amplifies GH release beyond either alone. Ipamorelin provides selective GH pulses without affecting cortisol or prolactin, while CJC-1295 sustains elevated GH levels.

How do you dose Ipamorelin and CJC-1295 together?

Standard protocol: Ipamorelin 100-300 mcg + CJC-1295 (no DAC) 100-300 mcg, taken 2-3 times daily. Usually taken together in the same injection. Common timing: morning (fasted), post-workout, and before bed.

Should I take them at the same time?

Take Ipamorelin and CJC-1295 together - they work best when combined in the same injection. Best taken on empty stomach (fasted state). Wait 20-30 minutes before eating. Before bed dosing enhances natural nighttime GH pulse.

Educational Information Only

This information about stacking Ipamorelin with CJC-1295 is for educational purposes only. Combining peptides should only be done under medical supervision. Individual responses vary - consult healthcare providers before use.